Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when JSPR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsJasper Therapeutics reports Q1 2026 financial results and corporate update
Filed May 14, 2026 · Period ending May 14, 2026 · ~1 min read
Key Changes
-
medium
Company issued press release disclosing financial results for the quarter ended March 31, 2026, along with operational updates. Specific metrics are in the attached exhibit.
Item 2.02 verify on EDGAR → -
low
The 8-K filing itself contains minimal detail; all substantive financial and operational information is contained in the furnished press release (Exhibit 99.1).
8-K: Exhibits verify on EDGAR →
Summary
Jasper Therapeutics filed an 8-K to announce its first quarter 2026 financial results and provide a corporate update. The filing is procedural in nature, with the actual financial metrics, cash position, and operational milestones contained in the attached press release rather than in the body of the 8-K itself. This is standard practice for quarterly earnings announcements outside of the regular 10-Q filing cycle.
For retail investors, the key information to review is the press release exhibit, which should detail Q1 revenue (if any), operating expenses, cash burn rate, and progress on clinical programs. Watch for the company's 10-Q filing in the coming weeks, which will provide full financial statements and management discussion of results. Also monitor any guidance updates or clinical trial milestones mentioned in the press release that could affect the company's runway and development timeline.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Jasper Therapeutics reported Q1 2026 financial results and provided a corporate update via press release.
Added in current filing · verify on EDGAR →
On May 14, 2026, Jasper Therapeutics, Inc. issued a press release reporting its financial results for the quarter ended March 31, 2026 and providing a corporate update.
The company disclosed its financial results for the first quarter ended March 31, 2026, along with a corporate update. The specific financial metrics and operational details are contained in the attached press release (Exhibit 99.1), which is furnished rather than filed with the SEC.
Event · Item 9.01 — Financial Statements and Exhibits
Jasper Therapeutics filed an 8-K attaching a press release dated May 14, 2026; no material business event disclosed in the filing body.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
99.1 Press Release, dated May 14, 2026.
The 8-K attaches a press release dated May 14, 2026 as Exhibit 99.1. The filing body itself contains no substantive disclosure of the event being announced; the material information is in the attached press release, which is not included in this filing text.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 10, 2026 · How we verify